Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Aytu BioPharma Inc. (AYTU:NASDAQ), powered by AI.
Aytu BioPharma Inc. is currently trading at $2.15. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Aytu BioPharma Inc. on Alpha Lenz.
Aytu BioPharma Inc.'s P/E ratio is -1.0.
“Aytu BioPharma Inc. trades at a P/E of -1.0 (undervalued) with modest ROE of -58.1%.”
Ask for details →Aytu BioPharma Inc. is a specialty pharmaceutical company dedicated to developing and commercializing innovative prescription therapeutics, with a particular emphasis on pediatric and pediatric-onset conditions. The company's diversified portfolio features treatments for attention deficit-hyperactivity disorder (ADHD), allergies, and fluoride deficiency, targeting prevalent and often underserved areas in patient care. Aytu BioPharma stands out for its patient-centric approach, exemplified by comprehensive support programs like Aytu RxConnect, which facilitate best-in-class patient access to therapies. The company’s growth strategy combines organic development with strategic in-licensing and acquisitions, regularly seeking new products that meet unmet needs or improve upon existing standards of care. Aytu BioPharma’s commercial operations and infrastructure support both prescription and consumer health segments, making it a notable contributor to advancing patient wellness in the broader pharmaceutical landscape.
“Aytu BioPharma Inc. trades at a P/E of -1.0 (undervalued) with modest ROE of -58.1%.”
Ask for details →Aytu BioPharma Inc. (ticker: AYTU) is a company listed on NASDAQ in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 82 employees. Market cap is $14M.
The current price is $2.15 with a P/E ratio of -1x and P/B of 0.71x.
ROE is -58.10% and operating margin is 3.82%. Annual revenue is $66M.